TL;DR: The Centers for Medicare & Medicaid Services modified NCD 101, its thyroid testing coverage policy, effective March 7, 2026. Here's what changes for billing teams.
This update to NCD 101 in the CMS system affects how Medicare covers thyroid function studies—including TSH, free T4, total T4, T3 uptake, and free thyroxine index (FTI) testing. The policy does not list specific CPT codes in the current data, but the clinical and frequency criteria carry real claim denial risk if your documentation doesn't match. If thyroid testing is a significant part of your lab or endocrinology billing, read this before March 7, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Medicare) |
| Policy | Thyroid Testing |
| Policy Code | NCD 101 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium |
| Specialties Affected | Endocrinology, Primary Care, Internal Medicine, Oncology, Psychiatry, Cardiology, Clinical Laboratory |
| Key Action | Audit your thyroid testing frequency and documentation against the two-per-year limit for clinically stable patients before March 7, 2026 |
CMS Thyroid Testing Coverage Criteria and Medical Necessity Requirements 2026
NCD 101 is the National Coverage Determination governing Medicare coverage of thyroid function studies. CMS uses this coverage policy to define when thyroid testing is medically necessary—and when it isn't.
The clinical scope here is wide. The Centers for Medicare & Medicaid Services covers thyroid testing for a long list of indications that goes well beyond obvious thyroid disease. Metabolic disorders, hyperlipidemia, certain anemias, unexplained depression, psychosis, cardiac arrhythmias, menstrual disorders, skin conditions, myalgias, and ophthalmologic disorders all qualify—if you can document the clinical rationale. That breadth is actually good news for labs and physicians with diverse patient panels.
The core diagnostic framework under NCD 101 centers on TSH, complemented by free thyroxine (fT-4) or total thyroxine (T4) with T3 uptake. The free thyroxine index (FTI) calculation applies when total T4 or T3 uptake is performed, specifically to correct for protein binding effects. Additional testing is recognized for complex diagnostic situations and hospitalized patients, where comorbidities can skew results.
What CMS Considers Medically Necessary
CMS thyroid testing coverage policy recognizes the following as medically necessary indications:
| # | Covered Indication |
|---|---|
| 1 | Distinguishing between primary and secondary hypothyroidism |
| 2 | Confirming or ruling out primary hypothyroidism |
| 3 | Monitoring hormone levels in patients with goiter, thyroid nodules, or thyroid cancer |
| 4 | Monitoring drug therapy in patients with primary hypothyroidism |
| 5 | Confirming or ruling out primary hyperthyroidism |
| 6 | Monitoring therapy in patients with hyperthyroidism |
The policy also extends medical necessity to patients with a personal history of malignant neoplasm of the endocrine system and to patients on long-term thyroid drug therapy who need follow-up testing.
The Frequency Rule — This Is Where Claims Get Denied
Here's the rule that matters most for your claim denial rate: CMS covers thyroid testing up to two times per year for clinically stable patients. That's the ceiling. Full stop.
More frequent testing is covered, but only under two conditions. The patient's thyroid therapy was changed. Or the patient shows new or returning signs or symptoms of hyperthyroidism or hypothyroidism. Document one of those two conditions clearly, or your third and fourth claims in a year will not survive a medical necessity review.
Prior authorization isn't explicitly required under NCD 101, but that doesn't protect you from post-payment audits. Your documentation has to hold up under medical necessity review. If your ordering physicians are running TSH panels on stable patients quarterly as a matter of routine, that pattern will flag.
CMS Thyroid Testing Exclusions and Non-Covered Indications
NCD 101 doesn't use the word "experimental" for any thyroid test. But the policy does draw a meaningful line through frequency.
Testing beyond two times per year on a clinically stable patient is not covered. Stability is the key variable. If the patient's therapy hasn't changed and they're showing no new symptoms, the medical necessity case for a third test in the same calendar year is weak. CMS's position is that modern TSH testing is specific enough that routine over-testing isn't clinically justified.
The policy also implicitly limits coverage to the tests described in the clinical framework—TSH, fT-4, total T4, T3 uptake, and FTI. Additional specialty tests ordered for complex or hospitalized patients need documentation of the specific clinical circumstances that made the standard panel insufficient.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Distinguish primary vs. secondary hypothyroidism | Covered | See billing guidelines | Document clinical rationale |
| Confirm or rule out primary hypothyroidism | Covered | See billing guidelines | Standard indication |
| Monitor thyroid hormone levels — goiter, nodules, cancer | Covered | See billing guidelines | Oncology and endocrinology |
| Monitor drug therapy — primary hypothyroidism | Covered | See billing guidelines | Up to 2x/year if stable |
| Confirm or rule out primary hyperthyroidism | Covered | See billing guidelines | Standard indication |
| Monitor therapy — hyperthyroidism | Covered | See billing guidelines | Up to 2x/year if stable |
| Metabolic disorders, malnutrition, hyperlipidemia | Covered | See billing guidelines | Document clinical connection |
| Certain anemias | Covered | See billing guidelines | Document type and clinical rationale |
| Unexplained depression, psychosis, personality disorders | Covered | See billing guidelines | Psychiatry and primary care |
| Cardiac arrhythmias | Covered | See billing guidelines | Cardiology and internal medicine |
| Disorders of menstruation | Covered | See billing guidelines | OB/GYN and primary care |
| Ophthalmologic disorders | Covered | See billing guidelines | Graves' ophthalmopathy pattern |
| Skin conditions, myalgias | Covered | See billing guidelines | Broad symptom-based coverage |
| Alterations in consciousness, malaise, hypothermia | Covered | See billing guidelines | Inpatient and ED settings |
| Personal history of malignant endocrine neoplasm | Covered | See billing guidelines | Follow-up testing |
| Long-term thyroid drug therapy | Covered | See billing guidelines | Routine follow-up |
| Testing >2x/year — clinically stable patient, no therapy change, no new symptoms | Not Covered | N/A | Frequency limit under NCD 101 |
| FTI calculation without total T4 or T3 uptake | Not Covered | N/A | FTI is only valid as a correction calculation |
CMS Thyroid Testing Billing Guidelines and Action Items 2026
The effective date of March 7, 2026, is your deadline. Here's what to do before then.
| # | Action Item |
|---|---|
| 1 | Audit your thyroid testing frequency data now. Pull claims from the last 12 months for thyroid-related lab work. Flag any Medicare patient who received more than two thyroid panels in a year. For each one, confirm the chart contains documentation of a therapy change or new symptoms. If the documentation isn't there, you have a vulnerability. |
| 2 | Standardize your documentation requirements with ordering physicians. The policy's breadth on covered indications is a double-edged situation. Yes, many conditions qualify. But "the patient seemed tired" doesn't close the loop on medical necessity. Build a simple ordering note template that captures the specific indication from the NCD 101 list. |
| 3 | Train front-line staff on the two-per-year frequency rule. Clinically stable patients get two tests per year. That's the rule under this coverage policy. Your schedulers, medical assistants, and order entry staff need to know this—not just your billers. Catching frequency overruns before the claim is submitted is far cheaper than working denials after the fact. |
| 4 | Review your ICD-10 diagnosis code pairings. The policy covers a wide range of conditions, but your thyroid testing billing depends on the diagnosis code telling that story. A TSH panel for a patient with unexplained depression needs the right ICD-10 to match the indication. If your coders are defaulting to generic thyroid codes when the real indication is something else on that list, you're leaving reimbursement accuracy on the table—and creating audit exposure. |
| 5 | Flag complex and inpatient cases separately. NCD 101 acknowledges that hospitalized patients and complex diagnostic situations may need additional testing beyond the standard framework. But that latitude requires documentation. Create a chart flag or order note type specifically for "complex thyroid workup—inpatient" so those cases get reviewed and documented before billing goes out. |
| 6 | Update your charge capture workflow to reflect the NCD 101 framework. If your billing system uses frequency edits, update the thyroid testing billing rules to enforce the two-per-year ceiling for stable patients before March 7, 2026. A pre-claim edit that flags the third claim in a year is far easier to work than a denial. |
If you're running a high-volume lab or a multi-specialty practice with significant thyroid testing across endocrinology, psychiatry, and primary care, talk to your compliance officer before the effective date. The breadth of covered indications makes this policy look permissive. The frequency limit makes it a real audit target.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Thyroid Testing Under NCD 101
A Note on Codes Under This Policy
The current NCD 101 policy data does not list specific CPT or HCPCS codes. CMS directs billing teams to the quarterly Covered Code Lists published alongside this NCD, which include both codes and narrative descriptions. You should pull those directly from the CMS Clinical Laboratory Fee Schedule resources.
This is not unusual for lab NCDs—CMS often manages the code-level detail through the quarterly lists rather than embedding codes in the NCD itself. The clinical laboratory fee schedule and the Covered Code Lists are your authoritative source for specific billing codes under this policy.
Action: Download the current CMS Covered Code List for NCD 101 from the Medicare Claims Processing Manual, Chapter 16 (formerly Chapter 120 for Clinical Laboratory). Cross-reference your charge master against that list before March 7, 2026.
The Medicare Claims Processing Manual also applies here. CMS cross-references NCD 101 to Chapter 120, Clinical Laboratory Services Based on Negotiated Rulemaking. Your billing guidelines for claim submission detail—including modifier requirements and claim-level edits—live there.
If you're billing through a Medicare Administrative Contractor that has issued a local coverage determination supplementing NCD 101, check your MAC's LCD for any additional code-level or documentation requirements that go beyond what the NCD specifies. MAC-level rules layer on top of the NCD, not in place of it.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.